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ABSTRACT
Nanotechnology is an area of growing public interest. Employing nanotechnology in the field of drug delivery has led to the advent of 
nanopharmaceuticals. Nanopharmaceuticals are bound to surmount various obstacles that the field of pharmacy is currently facing by offering various 
advantages thereby, a promising potential to formulate advanced medicines with fewer adverse effects. Extensive research is in place, thus instigating 
the development of novel drug delivery systems, such as carbon nanotubes, nanosponges, nano wafers, and nanofibers, to name a few. Since their 
inception, these nanopharmaceuticals have advanced significantly regarding their preparation strategy and scope of applications. This article aims to 
review the merits, limitations, and scope of these aforementioned delivery systems.
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INTRODUCTION
Nanopharmaceuticsis the branch of science that deals with the 
application of the principles of nanotechnology (the science of material 
featuring between 10−9 and 10−7 m) in pharmaceutics [1]. The nanoscopic 
size of these delivery systems helps in altering the aspects of a drug, 
including the bioavailability, bio-distribution, and pharmacokinetics. 
Nanoscaling the drug is another well-established technique for altering 
the properties [2]. Nanopharmaceuticals have unique properties due to 
their small size-it is this small size that allows them to reach places in the 
human body where larger particles do not have access to. For systemic 
applications, the generally accepted diameter of nanopharmaceuticals 
is in the range of 10–100 nm, with minimum surface charge [3]. 
Nanopharmaceuticals have a promising potential in the area of tissue 
engineering, in the field of drug delivery and diagnostics among many 
others. Current assertions of nanotechnology in pharmaceutical field 
are instigation of bioactive surfaces, advanced diagnostic, biomarker, 
image enhancement device, biosensor, implant technology, nanocarrier, 
nanomedicine, nanorobots, and tissue engineering to name a few [4]. 
Principally, nanopharmaceutical formulations are colloidal in nature 
of range 10–1000 nm in size and extensively used in drug delivery 
systems [5]. The purpose of the biomaterials employed in this field is 
primarily to improve drug delivery systems, imaging, and diagnostic 
technologies while the nanoscale materials are widely used in other 
industries such as electronics and optics [6,7]. The advantages of 
nanoparticle drug formulations include improved solubility, enhanced 
dissolution rate, improved oral bioavailability, improved dose 
proportionality, suitability for administration by all routes, and the 
possibility of sterile filtration due to decreased particle size range [7].
CARBON NANOTUBES (CNTS)
CNTs are allotropes of carbon with a tube-shaped structure. The 
diameter of the tubes are in the nanometer scale (can be as thin as a 
few nm yet having a length up to 100 microns). They have a thermal 
conductivity, mechanical and electrical properties. Nowadays, CNTs 
have found use in the medical field as they can be used for gene delivery 
to cells and organs as well as tissue regeneration [8].
CNTs can be classified as single-walled nanotubes and multi-walled 
nanotubes. As the name suggests, single-walled CNTs consist of one 
layer forming a cylinder while the multi-walled nanotubes comprise 
several cylindrical layers each having a diameter greater than the 
other. The chemical bonding in the tubes is best described by orbital 
hybridization (sp2-hybrid carbon atoms) which accounts for the unique 
strength of CNTs.
CNTS are widely researched in the field of drug delivery and biosensing 
methods for disease treatment and health monitoring. Table 1 lists 
some of the drugs explored for delivery using CNTs as carriers.
FUNCTIONALIZATION OF CNTS
It is the process of attaching an organic/inorganic molecule to the 
tubular structure of CNTs. This is done in an attempt to alter the 
physicochemical properties of the tube. Functionalization can be 
done through four methods: Noncovalent functionalization, covalent 
functionalization, endohedral filling and external decoration with 
inorganic materials [9].
ADVANTAGES OF CNTS
1. They have high electrical and thermal conductivity [10].
2. Due to their chemical bonding, they have unique tensile strength, 
and they have very high flexibility and elasticity.
3. They are available in small sizes which is helpful in penetrating 
tumors through the small holes or for the transportation of DNA.
4. They have a high surface area to volume ratio which aids in the 
effective transportation of molecules and rapid release. They also 
can contain a considerable amount of contents [11].
DISADVANTAGES OF CNTS
Health hazard:
1. Studies showed that the body could tolerate CNTs of relatively low 
length but as the length increased the use of the latter constituted 
some risks. Long tubes produced inflammation in sensitive tissues 
surrounding organs [12].
2. If CNTs are inhaled, due to their incredibly small size, it could lead to 
cancer (mesothelioma-a cancer form associated with asbestos) [13].
MANUFACTURE OF CNTS [14]
The following are the methods which can be employed for the 
production of CNTs:
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1. Arc discharge method
2. Laser method
3. Chemical vapor deposition method.
ARC DISCHARGE METHOD
This method is the simplest and most probably the easiest way to 
produce multi-walled CNTs. This technique produces a complex 
mixture of components which require purification to obtain the CNTs. 
It involves the arc-vaporization of two carbon electrodes placed in such 
a way that they are separated by a small gap in a closed environment 
filled with an inert gas at low pressure. A direct current (50–100 A) 
driven by a potential difference of 20 V generates a high-pressure 
discharge between the electrodes causing the vaporization of one of the 
electrode’s surface forming a rod-shaped deposit on the other carbon 
electrode.
LASER METHOD
This technique is also known as laser ablation method and it is used to 
produce high purity single-walled nanotubes.
Conditions used in this process are as follows:
• Argon at 67 kPa
• A flow rate of approximately 3 mm/s, and
• 25 mm inner tube.
The process is carried out by laser vaporization of a graphite rod-
containing nickel and cobalt at 1200°C in flowing argon followed by 
treatment by heat in a vacuum at 1000°C to eliminate C60 and other 
fullerenes.
The process is done using two successive laser pulses: The first laser 
breaks the graphite rod into large particles while the second laser 
breaks the large particles produced by the first laser producing smaller 
particles which are fed to the growing CNT. The use of 2 lasers helps in 
reducing the amount of carbon deposited as soot.
One of the major drawbacks associated with these two methods is 
that it is difficult to scale up the production to a larger industrial 
scale, that is, they can be used to produce only a little amount of CNTs 
at a time.
CHEMICAL VAPOUR DEPOSITION METHOD
This method can be used to produce both single-walled and multi-
walled CNTs. It can be used to produce large amounts of CNTs. It 
involves the catalytic vapor deposition of acetylene over cobalt and iron 
catalysts supported on silica. The amount of cobalt catalyst determines 
the activity of carbon deposition and the pH of the catalyst determines 
the selectivity of the CNT.
Carbon nanostructure with open ends was produced using acetylene 
at reaction temperatures of 545°C and 900°C for Nickel catalyzed and 
uncatalyzed processes, respectively.
High yields of single-walled CNT can be produced by the deposition of 
the H2/CH4 mixture over-dispersed metal particles (nickel, cobalt, and 
iron) on magnesium oxide at 1000°C.
APPLICATIONS OF CNTS
Drug delivery
Drugs can be attached to the CNTs on its surface or inside the tube 
which is then introduced into the patient through oral route or by 
injection. Cells ingest the CNTs and the tube releases its content into the 
cell, thus leading to drug delivery [15].
Drug release from the CNT is achieved at a faster rate than when 
compared to traditional dosage forms due to a large surface area to 
volume ratio.
Cancer therapy
CNTs are used as drug carriers to bring the anticancer drugs to the 
target site. The efficacy of present anticancer drugs is limited due to 
their narrow therapeutic window, systemic toxicity, and resistance by 
cells. CNTs can cross cytoplasmic and nuclear membranes, reaching 
the target cells in an intact form thus increasing the concentration of 
anticancer drugs at the target site [16].
The high surface area of CNTs allows the attachment of multiple drugs. 
CNTs can also be used for antitumor immunotherapy. This involves the 
stimulation of the immune system to combat the tumor cells. A cancer 
vaccine is incorporated in the nanotube and injected into the body to 
stimulate the immune system [17,18].
Infection therapy
Antimicrobial agents can be carried by functionalized CNTs and then 
be transported to mammalian cells. This method not only increases the 
therapeutic concentration at the target site but also reduces the toxicity 
of the antimicrobial agent in the systemic circulation.
For gene therapy by DNA delivery
Gene therapy is the process of correcting a defective gene by inserting a 
DNA molecule into the cell nucleus. This DNA transfer can be achieved 
by the use of CNTs. When inserted into the tube, the DNA molecule 
is protected from enzymatic breakdown and nucleic acid binding 
proteins [19]. It has been found that nanoparticles can penetrate hair 
follicle canal, thus allowing nanoparticulate formulations to be used 
selective gene delivery [20].
For the treatment of broken bones
CNTs imitate the role of collagen as the scaffold material formation for 
the growth of hydroxyapatite into bone (hydroxyapatite crystals and 
collagen fibers are components of the bone tissue) [20].
Tissue regeneration and artificial implants
CNTs are extensively used for the development of scaffolds due to the 
following reasons: biocompatibility, resistance to biodegradation, and 
capability for functionalization to improve organ regeneration. CNTs 
can be used to improve the conductivity and mechanical strength of 
tissue scaffolding [21].
Neurodegenerative diseases (Alzheimer’s disease)
Due to their very small size, CNTs can easily cross the blood-brain 
barrier and thus can be used along with drugs to target the brain to 
treat neurodegenerative diseases [21,22].
Diagnostic purposes
CNTs can be used as biosensors for the detection of various analytes.
NANOSPONGES
Nanosponges are hypercrosslinked polymer based virus-sized sponges, 
which can be infused with various drugs. These virus-sized sponges 
offer high drug loading compared to other nanocarriers. They can 
move throughout the biological system until they come in contact 
with the definite target site following which they adhere to the surface 
and deliver the drug in a controlled and predictable manner [29]. 
Nanosponges have wide application in drug delivery (Table 2).
Table 1: Application of CNTs as carriers for drug delivery
Drug Indication Reference
Amphotericin B Anti-fungal [23]
Cisplatin Cancer (sarcoma, carcinoma) [24]
Doxorubicin Cancer [25]
Epirubicin Breast cancer [26]
Oxaliplatin Metastasized rectal cancer [27]
Paclitaxel Cancer [28]
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ADVANTAGES [30-36]
1. Predictable releases: Nanosponges do not show burst effect upon 
reaching the target.
2. The controlled release nanoparticle drug delivery system may be 
instigated to deliver anticancer therapies, like injecting the drug 
directly into the tumor site.
3. Effective release of drug: Since the drug releases directly at the tumor 
site instead of moving freely through the body, it is more effective for 
a given dosage. Furthermore, they have fewer side effects as smaller 
amounts of the drug interact with the healthy tissues.
4. Encapsulating the anticancer drug in nanosponge permits the use of 
lipophilic drugs (low solubility in water) since nanosponge particles 
are soluble in water.
5. Improved stability (over a range of pH 1–11; temperature up to 130°C).
6. Enhanced elegance and flexibility of formulation. Nanosponge 
systems are non-irritant, nonmutagenic, nonallergic, and nontoxic.
7. A nanosponge provides an extended-release action (continuous 
action over a period of 12 h).
DISADVANTAGES/LIMITATIONS
1. Nanosponges can incorporate only molecules which are small in 
size [37].
2. Nanosponges may either be in para-crystalline or in crystalline 
form. The extent of crystallization decides the loading capacity of 
nanosponges [37].
POLYMERS USED IN NANOSPONGE PREPARATION
Polymers and crosslinkers are crucial in the fabrication of nanosponges. 
Polymer type decides the formation and release, whereas crosslinker 
converts molecular cavities into three-dimensional nanoporous 
structures [37].
a. Polymers: Cyclodextrins and its derivatives such as methyl 
β-cyclodextrin, alkyloxycarbonyl cyclodextrins, 2-hydroxypropyl 
β-cyclodextrins; hyper cross-linked polystyrenes, copolymers like 
poly(valerolactone-allylvalerolactone) and poly(valerolactone-allylval
erolactoneoxepanedione), ethyl cellulose and polyvinyl alcohol (PVA).
b. Crosslinkers: Diaryl carbonates, Diphenyl carbonate, diisocyanates, 
carbonyldiimidazoles, pyromelliticanhydride, epichloridrine, 
carboxylic acid dianhydrides, glutaraldehyde, 2,2-bis(acrylamido) 
acetic acid and dichloromethane have been reported as crosslinkers.
PREPARATION OF NANOSPONGES
Emulsion solvent diffusion method
Ethyl cellulose and PVA are used in different ratios to prepare 
nanosponges. The dispersed phase consisting of the drug and 
ethylcellulose is dissolved in dichloromethane and gradually added to 
a certain quantity of PVA in an aqueous continuous phase. The reaction 
mixture is mixed at 1000 rpm for 120 min. The nanosponges thus 
prepared are obtained by filtration and are further kept for drying in 
the oven at 400°C for 24 h. To ensure the removal of residual solvent, 
the dried nanosponges are stored in vacuum desiccators [38].
Ultrasound-assisted synthesis
This method of preparation involves the reaction of polymers with 
the cross-linkers under the effect of sonication. This is done in the 
absence of a solvent. The nanosponges formed are uniform in size 
and spherical in shape. The polymer and the cross-linker are mixed in 
a certain molar ratio in the flask. The flask is placed in an ultrasound 
bath of water and is heated to 90°C. The mixture is then sonicated for 
5 h. Once the mixture cools down, the product is broken forcibly. The 
non-reacted polymer is removed by washing the product with water, 
and consequently, soxhlet extraction with ethanol is done to cleanse the 
product. The final product is then dried under the vacuum and stored at 
25°C until future use [38].
Hyper cross-linked β-cyclodextrins
Dimethyl formamide (DMF) is taken in a round-bottomed flask, 
anhydrous β-cyclodextrin is added to obtain complete dissolution. 
Carbonyl di-imidazole (61.42 m mol) is subsequently added. The 
solution is left undisturbed to react for 4 h at 1000 C. After the 
completion of condensation polymerization, the transparent block of 
hyper cross-linked cyclodextrin is roughly ground followed by addition 
of an excess of deionized water to remove DMF. Unreacted reagents or 
residual by-products are eliminated by soxhlet extraction with ethanol.
A white powder is obtained, and it is allowed to dry in an oven at 60°C 
overnight. The fine powder obtained is dissolved in water. The portion that 
remained suspended in water is recovered and lyophilized. The obtained 
nanosponges are spherical in shape and sub-micron in dimension [39].
Loading of the drug into nanosponges
Nanosponges employed for drug delivery should undergo a pretreatment 
to attain an average particle size of below 500 nm. The nanosponges are 
suspended in water followed by sonication to break aggregates if any. 
The suspension is then centrifuged to obtain the colloidal fraction after 
which the supernatant is separated, and the sample is dried by freeze 
drying. An aqueous suspension of nanosponge is prepared, and an excess 
amount of drug is dispersed in the latter. Constantly, stir the suspension 
for the specific time required for complexation. The complexed drug 
is then separated from the uncomplexed drug by centrifugation soon 
after complexation takes place, where the uncomplexed drug is the 
undissolved part. The solid crystals of nanosponges are obtained, either 
by freeze-drying or solvent evaporation [39].
Solvent method
The polymer is added to a suitable solvent, primarily a polar aprotic 
solvent such as DMF or dimethylsulfoxide. This mixture is added to 
crosslinker (e.g., carbonyl di-imidazole and dimethyl carbonate) in 
excess quantity; the required ratio for crosslinker/molar ratio is as 1:4. 
The reaction is carried out at a temperature ranging from 100°C to the 
reflux temperature of the solvent, and the time ranging from 1 to 48 h. 
As soon as the reaction is completed, the solution is allowed to cool to 
room temperature, and the product is added to a large quantity of bi-
distilled water and product is recovered by filtration under vacuum and 
subsequently purified by prolonged soxhlet extraction with ethanol. 
Finally, the product is dried under vacuum and ground in a mechanical 
mill to produce a homogeneous powder [40].
Factors influencing the formulation
1. Polymer type: Formation and the potential of nanosponges can be 
influenced. Cavity size of nanosponges should be appropriate for 
complexation.
2. Temperature alteration: Drug/nanosponges complexation can be 
affected by temperature alterations. As the temperature increases, 
the magnitude of apparent stability constant of the drug decreases 
possibly due to the reduction of drug interaction forces.
3. Preparation method: Drug complexation can be affected by the 
method of loading drug into nanosponges. Nature of drug and 
polymer alter the effectiveness of the method.
Table 2: Applications of nanosponges
Drug Indication Reference
Alprostadil Erectile dysfunction [46]
Camptothecin Prostate tumor and thyroid cancer [47,48]
Cefadroxil Broad spectrum antibiotic [49]
Celecoxib NSAID [50]




Nifedipine Angina pectoris [56]
Paclitaxel Cancer [45]
Resveratrol Inflammation, breast cancer [57]
Rilpivirine HIV [58]
Tamoxifen Breast cancer [59]
Quercetin Anticancer [60]
NSAID: Nonsteroidal anti-inflammatory drug
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4. The degree of substitution: The type, number, position of 
the substituent on parent molecule can greatly influence the 
nanosponges and hence, its complexation is affected.
APPLICATIONS OF NANOSPONGES
Topical agents (e.g., econazole nitrate-antifungal)
Nanosponge delivery system is the exclusive method for controlled 
release of topical agents and retention of drug form on the skin. Topical 
nanosponges can be easily formulated, for example, local anesthetics, 
antifungal, and antibiotics. With current topical medicaments, rashes 
or worse adverse effects can be observed when active pharmaceutical 
ingredients enter the skin. On the contrary, nanosponges allow an even 
and sustained rate of release, reducing irritation while maintaining 
efficiency. A variety of formulations, including gel, lotion, cream, 
ointment, liquid, or powder can be incorporated with nanosponges [41].
Solubility enhancement (e.g., itraconazole)
Nanosponges can be used to enhance the solubility and rate of 
dissolution of poorly soluble drugs while providing a controlled release 
profile. However, molecular dimensions and conformation are vital 
factors altering complexation process and hence may not be applicable 
to all molecules. Nanosponges of cefpodoxime proxetil have shown a 
better dissolution rate than regular cefpodoxime proxetil [39].
Sustained delivery (e.g., acyclovir)
Acyclovir is widely used to treat herpes simplex virus infections. 
The absorption of the drug in the GIT is slow, and thus appropriate 
concentrations of drug cannot be achieved at the target site. 
Encapsulation of acyclovir in nanosponges showed an increased 
efficacy of the drug [42,43].
Oxygen delivery systems
Nanosponge has the capability of storing and releasing oxygen gradually 
over time. Oxygen-filled nanosponges can be used to supply oxygen to 
hypoxic tissues in certain diseases e.g., cyclodextrinnanosponges [44].
Anticancer chemotherapy (e.g., paclitaxel)
Drugs are incorporated in nanosponges, and they expose a targeting 
peptide that binds to radiation-induced cell surface receptor on the 
tumor. Once the nanosponge encounters a tumor cell, they adhere to 
the surface and trigger to release the contents. Such an example is 
paclitaxel (Taxol-20) [45].
NANOWAFERS
Nanowafer refers to a nanoscopic clear circular disc which can be 
administered on the surface of the eye and can resist blinking without 
getting dislocated. It consists of an assemblage of drug-loaded 
nanoreservoirs from which the drug will be released in a strongly 
controlled manner for several hours or days. The resultant contact time 
of the drug with the eye is increased, along with the net bioavailability 
because of its slow release. Once the drug is released, the wafer dissolves 
and gets dwindled [61]. The nanowafer is made up of a water-soluble 
polymer, which starts dissolving on application, thus releasing its payload. 
Sustained release and increased corneal permeability of nanowafer 
delivered doxycycline were compared with topical eye drops, increasing 
corneal residence time from a few minutes to up to 24 h in mice. These 
results demonstrate the immense scope for utilizing nanoporous 
materials to surmount the limitations of ocular drug delivery [62]. 
Nanowafers have tremendous potential in ocular drug delivery (Table 3).
ADVANTAGES OF NANOWAFERS OCULAR DRUG DELIVERY (OVER 
EYE DROPS) [61,63-65]
1. Does not need refrigeration.
2. Can be used for controlled release of an ocular drug.
3. Easy to fabricate.
4. Better patient compliance, especially for children and the elderly, 
because of lower dosing frequency (releases the drug over a period 
of hours or days).
5. Better bioavailability (on an average, only 5% of drug applied as an 
eye drop actually reaches past the cornea).
6. Fewer side effects (high systemic absorption using eye drops hence 
possibly causing significant side effects).
7. Increased therapeutic efficacy. (Does not get drained by nasolacrimal 
fluid).
8. Discrete doses and better quantification of the drug administered.
DISADVANTAGES OF NANOWAFERS [66]
1. Safety is controversial (their small size, which makes them useful, 
could also make them toxic).
2. Inadequate drug loading.
3. Further studies must be done to ensure that the vision would not be 
affected upon application of nanowafers.
4. Self-administration may be difficult for children and the elderly.
5. Nanowafers, being solid in nature, may be felt by the (often too 
sensitive) patients as an alien body in the eye, thus leading to 
a formidable physical and psychological impediment to user 
recognition and compliance.
METHOD OF PREPARATION
Nanowafers can be fabricated using various polymers, including PVA, 
polyvinylpyrrolidone, hydroxypropyl methylcellulose, and carboxy 
methylcellulose. The selection of these polymers is made based on 
their solubility in water, biocompatibility, mucoadhesivity, limpidity, 
and film-forming properties required to easily stick to a moist mucosal 
surface and adjust to the curvature of the eye. The nanowafers are 
prepared by the hydrogel template strategy with a few modifications. 
The process is explained in Fig. 1.
APPLICATIONS (CURRENT AND FUTURE PROSPECTS)
1. Once a week treatment of dexamethasone nanowafer has proven to 
be as effective as twice a day dexamethasone eye treatment in corneal 
wound healing and the suppression of corneal neovascularization [51].
2. Advancements in development of cysteamine (Cys) delivery 
nanowafer for corneal cystinosis (a rare metabolic disease, causing 
aggregation of cystine crystals in the cornea resulting in opacity of 
the cornea and loss of sight) The disease is currently managed with 
topical Cys eye drops (6–12 times daily throughout the patient’s 
life), which result in side effects such as eye pain, redness, and 
ocular inflammation. Hence, compliance and treatment outcomes 
are severely jeopardized. To overcome these issues, scientists have 
developed a clinically translatable cysteaminenanowafer, which can 
be simply applied to the eye with a fingertip. During the drug release, 
cysteaminenanowafer gradually dissolves and fades away.
3. Drug delivery system along with lubricant action.
4.  Nanowafer formulations for dry eye, ocular infections, eye injuries, 
and glaucoma.
NANOFIBERS
Nanofibers are fibers whose diameters are equal to or <100 nm.
Different polymers can be used to manufacture nanofibers of different 
diameters. Some of the polymers that can be used are natural polymers: 
Collagen, cellulose, gelatin, keratin synthetic polymers: Polylactic acid, 
polycaprolactone, polyurethane, and polylactic-co-glycolic acid [72,73].




4. Thermal-induced phase separation.
Of all the manufacturing processes mentioned, electrospinning is the 
most preferred. This is due to its easy setup, continuous production of 
nanofibers using various polymers and the ability to produce ultrathin 
fibers with variable dimensions and orientations [74].
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ADVANTAGES OF USING NANOFIBERS AS PHARMACEUTICALS [75]
1. A high surface area to volume ratio
• Due to its very small dimensions, nanofibers have a high surface 
area to volume ratio, and this will cause them to react at a faster 
rate. The rate of diffusion of drugs incorporated in the fibers will 
be higher compared to usual drug delivery systems.
2. Numerous polymers can be used for manufacture
• Using the electrospinning method, a wide variety of polymers 
can be used to manufacture nanofibers. Although nanofibers 
are mainly prepared from polymers, it has been found out 
that nanofibers can be produced using ceramic and metal by 
electrospinning of their precursor material.
3. Ease of manufacture
• Different materials can be easily mixed to produce fibers by 
spinning.
4. Ease of functionalization
• The effectiveness of nanofibers can be achieved by simple 
blending of polymer solution before spinning or core-shell 
electrospinning setup.
• The fibers can also be easily deposited on surfaces with a lower 
static charge such as metal, glass, and microfibrous mat.
5. Low cost of production and mass production is possible.
6. Nanofibers can be used as drug carriers for the controlled drug 
delivery of bioactive molecules.
DISADVANTAGES OF NANOFIBERS
The disadvantages of nanofibers are usually associated with its 
production method. While using electrospinning method, the 
drawbacks can be as follows:
1. The solvents used might be toxic and injurious to health.
2. Obtaining a 3D structure can be quite a tough task and obtaining the 
required pore size for medical applications is no difference.
3. The process also depends on several variables. (mentioned in the 
process of electrospinning).
PROCESS OF MANUFACTURE OF NANOFIBERS [76-78]





4. Thermal-induced phase separation.
Electrospinning is usually preferred due to its flexibility and cost-
effectiveness.
The process of electrospinning is explained in Fig. 2:
As depicted in Fig. 2, the polymer solution (polymer+solvent) is kept in 
a syringe connected to a high voltage supply. The solution is pumped 
Table 3: Applications of nanowafers in drug delivery
Drug pathological use Reference
Axitinib Corneal wound healing, corneal neovascularization [61]
Brimonidine Antiglaucoma [67]
Ciprofloxacin Antibiotic [68]
Cyclosporine Immunomodulator: Increases tear production in dry eye disease [64]
Cysteamine hydrochloride Treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis [69]
Dexamethasone Dry eye disease [70]
Doxycycline Ocular rosacea [61]
Hydrogen sulfide Glaucoma and retinal neurodegeneration [71]
Sorafenib Ocular cancer [61]
Sunitinib Ocular melanoma and Von Hippel-Lindau syndrome. [61]
Fig. 1: Method of preparation of nanowafer
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from the syringe at a uniform rate, forming a droplet at the tip of the 
needle. When the surface tension is overcome by the electrostatic 
repulsion of charges within the solution, the droplet is ejected (forming 
a jet) towards the collector which is connected to the ground as shown 
in the diagram. During the travel from the needle to the collector the 
solvent gets evaporated, and the jet is elongated at very high strain 
rates.
Formation of nanofibers is achieved by repulsion occurring among 
charges resulting in high stretching of the polymer stream. At first, the 
stream flows straight. On the way to the collector, the jet is elongated 
by whipping and bending processes caused by electrostatic repulsion 
initiated at small bends in the fiber, until it is finally deposited on the 
collector. The thinning and elongation of this resultant fiber leads to 
the formation of uniform fibers. The coiling movement of the stream 
increases the path between the needle and the collector, resulting in a 
considerable stretching (nanometer diameter).
The main forces acting on the drop and the traveling jet are:
1. External electrostatic field
2. Electrostatic repulsion among the charges
3. Surface tension
4. Forces associated with the viscoelasticity of the polymer.
Parameters affecting the electrospinning process:
1. The viscosity of solution - a high viscosity will prevent the breakage 
of the jet during the process and maintain the fiber shape and prevent 
the formation of beads.
2. Solution surface tension and electrical conductivity.
3. The dielectric constant of the solvent.
4. Applied voltage.
5. The flow rate of solution and diameter of the needle.
6. The distance between needle and collector and type of collector used.
APPLICATIONS OF NANOFIBERS (Table 4)
Drug delivery
Nanofibers can be used as drug carriers. Due to their high surface 
area to volume ratio, drug release occurs at a faster rate resulting in 
an increased bioavailability of the drugs, especially for poorly soluble 
drugs [79,80].
Wound healing
These involve the use of nanofiber layers produced from biopolymers 
(chitosan, gelatin, collagen amongst others/combination of these 
materials).
They can be used as wound dressings for the support during the wound 
healing process. Other substances can be incorporated in the nanofibers 
during the wound healing process, for example, an antibacterial agent 
can be added when using nanofibers on contaminated wounds and 
growth factors can be added when the proliferation of dermal tissue is 
needed [79,81].
Tissue engineering
Nanofibers made from biopolymers (e.g., collagen) can act as substrates 
for culturing cells. Different scaffolds can be prepared for implantation. 
The scaffolds are prepared based on the mechanical and structural 
properties of the nanofibers. A patient’s cells can be isolated and 
grown on nanofibers substrates which can be eventually used for tissue 
replacement purposes. Bioactive materials such as immunosuppressant 
and growth factor can be incorporated during the preparation of these 
scaffolds [79,82,83].
Barrier textiles
Textiles-containing hydrophobic nanofiber layers can be used as a 
barrier for bacterial contamination. The barrier textiles in which the 
nanofiber layer are enclosed between a carrier layer and a covering 
layer, are prepared as a “sandwich.” (Melt-blown non-woven). These 
particular textiles can be used as surgical dressings [84].
Topical delivery
Nanofibers have been modified to be able to accommodate vitamins and 
gold particles to be used as a facial mask for topical delivery. Existing 
beauty face masks can cause the degradation of sensitive ingredients 
(e.g., ascorbic acid). Thus, to circumvent this difficulty, a novel face 
mask has been manufactured to be able to contain and deliver multiple 
skin nutrients [85].
CONCLUSION
Nanopharmaceuticals are an integral part of modern medicine and drug 
delivery system. They have engendered a wide scope for revolutionizing 
the health-care sector in providing the drugs at the localized targets 
for a sufficient duration. These novel delivery systems enhance the 
solubility of poorly soluble drugs, decrease the dosing frequency and 
improve bioavailability. Nanowafers, in particular, have led to the 
formulation of novel formulations for indications of glaucoma, dry eye, 
corneal cystinosis and other eye-related problems such as injuries and 
Fig. 2: Electrospinning process
Table 4: Applications of nanofibers in drug delivery
Drug Indication Reference
Naproxen NSAID [86]




Fluconazole Vaginal candidiasis [89]
Insulin Diabetes [90]
Fusidic acid Steroid antibiotic [91]
Gentamicin Anti-bacterial [92]
Carmustine Cancer [93]




Tetracycline Periodontal diseases [96]
NSAID: Nonsteroidal anti-inflammatory drug
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infections. In general, nanopharmaceuticals has assisted in formulating 
advanced dosage forms and finished products. Currently, extensive 
research is in progress to discover wider horizons for the applications 
as well as to minimize the limitations of this technology.
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